Phase i Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

Cancer Immunology Research

Volumn 3, Issue 11, 2015, Pages 1248-1256

  Heery, Christopher R ^a   Singh, B Harpreet ^a   Rauckhorst, Myrna ^a   Marté, Jennifer L ^a   Donahue, Renee N ^a   Grenga, Italia ^a   Rodell, Timothy C ^b   Dahut, William ^a   Arlen, Philip M ^a   Madan, Ravi A ^a   Schlom, Jeffrey ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GlobeImmune Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; FUNGUS VACCINE; GI 6301; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRACHYURY; UNCLASSIFIED DRUG; BRACHYURY PROTEIN; FETOPROTEIN; INACTIVATED VACCINE; T BOX TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ADULT; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER GROWTH; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; LYMPHOCYTE COUNT; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; SACCHAROMYCES CEREVISIAE; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME; VACCINATION; AGED; BREAST NEOPLASMS; CELLULAR IMMUNITY; CHORDOMA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; IMMUNOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHORDOMA; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; FETAL PROTEINS; HUMANS; IMMUNITY, CELLULAR; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SACCHAROMYCES CEREVISIAE; T-BOX DOMAIN PROTEINS; VACCINES, INACTIVATED;

EID: 84945561165     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0119     Document Type: Article

References (33)

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
2. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
3. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov 2014;13:497-512.
4. Gravdal K, Halvorsen OJ,Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13:7003-11.
5. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of Ecadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-54.
6. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, amaster regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
7. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C. Cancer vaccines targeting the epithelial-mesenchymal transition: Tissue distribution of brachyury and other drivers of themesenchymal-like phenotype of carcinomas. Semin Oncol 2012;39:358-66.
8. Fernando RI, LitzingerM, Trono P, Hamilton DH, SchlomJ, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010;120:533-44.
9. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: An opportunity for novel interventions against lung cancer. Clin Cancer Res 2012;18:3868-79.
10. Haro A, Yano T, KohnoM, Yoshida T, Koga T, Okamoto T, et al. Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. Ann Surg Oncol 2013;20 Suppl 3:S509-16.
11. Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, Wasielewski R, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer 2011;47:1080-5.
12. Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. Overexpression of the EMT driver brachyury in breast carcinomas: Association with poor prognosis. J Natl Cancer Inst 2014;106.
13. Pinto F, Pertega-Gomes N, Pereira MS, Vizcaino JR, Monteiro P, Henrique RM, et al. T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin Cancer Res 2014; 20:4949-61.
14. Ben-Hamo R, Gidoni M, Efroni S. PhenoNet: Identification of key networks associated with disease phenotype. Bioinformatics 2014;30:2399-405.
15. Miettinen M, Wang Z, Lasota J, Heery C, Schlom J, Palena C. Nuclear brachyury expression is consistent in chordoma, common in germ cell tumors and small cell carcinomas, and rare in other carcinomas and sarcomas: An immunohistochemical study of 5229 cases. Am J Surg Pathol 2015 Apr 4. [Epub ahead of print].
16. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157-65.
17. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: Current concepts, management, and future directions. Lancet Oncol 2012;13:e69-76.
18. Amichetti M, Cianchetti M, Amelio D, Enrici RM, Minniti G. Proton therapy in chordoma of the base of the skull: A systematic review. Neurosurg Rev 2009;32:403-16.
19. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer 2004;101:2086-97.
20. Chen YL, Liebsch N, Kobayashi W, Goldberg S, Kirsch D, Calkins G, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976) 2013;38: E930-6.
21. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012;30:914-20.
22. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol 2013;24:1931-6.
23. Kabolizadeh P, Chen YL, Liebsch NJ, Hornicek FJ, Schwab JH, Choy E, et al. Analysis of tumor response in mobile spine and sacral chordoma treated with definitive high dose photon/proton radiotherapy (abstract). In Proceedings of the 54th Annual Conference of the Particle Therapy Co-Operative Group (PTCOG), 2015 May 18-23; San Diego, CA.
24. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007;13:2471-8.
25. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 doseescalation trial. Lancet Oncol 2012;13:501-8.
26. Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014;63:225-34.
27. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, et al. Immunological targeting of tumor cells undergoing an epithelialmesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 2013;4:1777-90.
28. Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 2008;14:4316-25.
29. Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, et al. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunol Immunother 2014;63:1307-17.
30. Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 2011;71:5296-306.
31. Stacchiotti S,Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009;20:1886-94.
32. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Bone Cancer [Internet]. [Accessed 2015 May]. Updated as version 1: 2014 Aug 8. Available from: Http://www.nccn.org/professionals/physician-gls/pdf/bone.pdf.
33. Hodge JW, Kwilas A, Ardiani A, Gameiro SR. Attackingmalignant cells that survive therapy: Exploiting immunogenic modulation. Oncoimmunology 2013;2:e26937.